Search
Actelion news update
3 min read
Actelion creates Vaxxilon together with the Max Planck society
ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck...
Actelion creates Vaxxilon together with the Max Planck society
How sustainable are branded generics?
Drug Name Confusion: why you need professional naming
How drugmakers come up with evocative brand names like Viagra and Lunesta
Help to find a new name for the monkeypox virus
How Do Drugs Get Named?
Sanofi launches Impact® brand of medicines for low-income countries
Branded Generics: What They Are and Why They’re Profitable
The top 20 drugs by worldwide sales in 2021
Drug submissions: Procedures to reach regulatory approval
How pharmaceutical names influence the way consumers and doctors view medicines
All in a name: safety first
Drug Name Development: Regulatory Changes You Need to Know
Drug repurposing and skinny labels
Pharma product launch optimisation tool
Naming Your Brand
Biosimilar Naming Policy Will Help Ensure Patient Safety and Transparency
How does the FDA 'approve' medical products?
The Secret Formula Behind Every Drug Name
Branding and design in the medical/pharma industry
Pharma Brand Strategy 2.0
What Is an Active Pharmaceutical Ingredient (API)?
The Drug Naming Process
The twists and turns of naming diseases
Branding: When One is Not Enough
Liposomal medicine names to be changed to avoid errors
The difference between pharmaceutical and biotechnology
Biosimilar names may affect pharmacist dispensing habits
Branders give products an identity
The top 10 drugs of 2024
FDA Draft Guidance Requiring Distinct Naming for Biosimilars
A drug by any other name would work just as well — making sense of drug names
FDA Approves First Sensor Pill to Alert Doctors When It’s Ingested
Can you teach old drugs new tricks?
'Accelerated approval' drugs: How well are they studied?
The FDA just approved the first direct competitor to a billion-dollar cancer drug
Role of brand is 57% more likely to influence a recommendation compared to two years ago
What’s in a name? Billions of dollars in tech costs for biosimilars
How drug development is speeding up in the cloud
Globalization in the pharmaceutical industry
Why Biosimilar Drug Names Contain Unhelpful Gibberish
Behind potent drug names, a complex mix of ingredients
Introducing The New Association For Accessible Medicines (AAM)
FDA Reiterates Decision on Suffixes in Biosimilar Naming
Behind potent drug names, a complex mix of ingredients
New diagnostic name for stigmatizing term obesity
The creative science of coining drug names
UK medicines regulation: responding to current challenges
Probiotics in Favor of Life
Maintaining Relevance In The Age Of Consumerism: Lessons From The Healthcare Industry
'Creation engineering': The art and science of naming drugs